Bittensor Subnet 68 Screens 11 Million Molecules in Decentralized Drug Discovery Race

TLDR:

• Bittensor Subnet 68 has already screened over 11 million molecules across nine disease targets.
• Three live competitions cover molecule screening, nanobody design, and search optimization.
• Yuma Consensus rewards high-quality research outputs through stake-weighted validator agreement.
• Metanova Labs uses decentralized miners to accelerate drug discovery at lower operational cost.

Bittensor is currently running a live drug discovery operation through Subnet 68. Metanova Labs built the subnet to reduce the high cost of early drug development. So far, 11 million small molecules have been screened across nine active disease targets.

Miners compete to find the best candidates, while validators judge quality through Yuma Consensus. The OpenTensor Foundation has publicly pointed to SN68 as proof of the network’s broader purpose.

Three Simultaneous Competitions Running on Subnet 68

Three separate competitions are running at the same time on Subnet 68. Each targets a different layer of the drug discovery process.

This structure lets the network tackle screening, design, and search strategy all at once. Together, they form a coordinated decentralized research effort with real financial stakes.

The first competition involves small molecule screening across nine active disease targets. Miners work to identify the strongest candidates from among millions of options. The best contributors earn TAO emissions, while low-quality submissions receive no reward.

The second competition centers on nanobody design, targeting PD-L1, a critical marker in cancer immunotherapy. Around 4,200 nanobody structures are under evaluation by competing researchers.

Crypto analyst @2xnmore noted on X that no centralized lab could match this volume of candidate output. The post described Subnet 68 as evidence that decentralized competition can outpace traditional research pipelines.

The third competition focuses on improving the methods used to search chemical space. Sixty-three unique algorithms are competing to explore that space more efficiently than rival approaches. The goal is not only to find good molecules but to build better tools for finding them.

Yuma Consensus Powers Bittensor’s Incentive Framework Across Any Problem Type

Yuma Consensus is the mechanism Bittensor uses to judge output quality across all its subnets. It operates through stake-weighted agreement and does not depend on the type of problem. This design allows it to evaluate drug discovery outputs just as it processes AI language model results.

The pharmaceutical industry spends billions of dollars before a single molecule reaches clinical trials. The chemical search space is too vast for any single organization to cover efficiently. A decentralized network of competing miners can screen millions of candidates at lower cost and higher speed.

This is where Bittensor’s competitive structure becomes relevant to real-world research. Anonymous miners contribute without institutional barriers, driven entirely by TAO emissions. The network removes bottlenecks that typically slow traditional pharmaceutical development pipelines.

Jacob Steeves hosted a full episode with the Metanova Labs team, which the OpenTensor Foundation shared publicly. This places Subnet 68 within the core team’s own stated vision for the network.

Drug discovery, more than any other live application on Bittensor, shows what incentive-driven decentralization can produce. It applies that model to a problem with measurable outcomes and real consequences for human health.